-
公开(公告)号：US20230406947A1
公开(公告)日：2023-12-21
申请号：US18094151
申请日：2023-01-06
发明人： Michael CROFT , Rana HERRO
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06
CPC分类号： C07K16/2878 , A61K39/3955 , A61K45/06 , A61K2039/505
摘要： Methods of treating inflammatory conditions, disease and disorders of skin are provided. Methods include, for example, contacting or administering a sufficient amount of a LIGHT inhibitor to a subject to treat skin inflammation, skin fibrosis, or a skin fibrotic disease or disorder such as scleroderma, atopic dermatitis, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema, keloid, sclerodactyly, or eosinophilic fasciitis.
-
公开(公告)号：US11806393B2
公开(公告)日：2023-11-07
申请号：US16537447
申请日：2019-08-09
发明人： Sujan Shresta
CPC分类号： A61K39/12 , C07K7/06 , G01N33/505 , G01N33/6893
摘要： The present application relates to composition of matter, processes and use of composition of matter relating to flavivirus peptides and epitopes, for example, for therapeutic or preventative vaccination against a flavivirus, and/or for inducing, enhancing, or sustaining an immune response against a flavivirus, and/or for detecting an infection with or an exposure to a flavivirus in a subject. The flavivirus may be for example the Zika and/or Dengue virus.
-
公开(公告)号：US11517615B2
公开(公告)日：2022-12-06
申请号：US16609784
申请日：2018-05-03
发明人： Shane Crotty , Jennifer Dan
IPC分类号： A61K39/00 , A61K39/09 , A61P37/04 , A61P31/04 , A61K35/17 , G01N33/563 , G01N33/569
摘要： Recurrent tonsillitis disease (RT) is a common indication for pediatric tonsillectomy, the most frequent childhood surgery. It is unknown why some children develop RT. The present disclosure demonstrates that RT tonsils exhibit significantly smaller germinal centers than non-RT tonsils, concomitant with a bias against Group A Streptococcus (GAS)-specific germinal center follicular helper CD4+ T cells (GC Tfh), and significantly reduced antibodies to the GAS virulence factor SpeA. The present disclosure also shows a significant immunogenetic component to this disease, with the identification of ‘at risk’ and ‘protective’ HLA alleles for RT. Finally, the present disclosure identifies a new cell type, granzyme B+GC Tfh cells, which are activated by SpeA, are significantly more abundant in RT GC Tfh cells, and have the capacity to kill B cells, thus, providing a window into the immunology and genetics of a classic childhood disease and identifies a new type of pathogenic T cell.
-
公开(公告)号：US20220365091A1
公开(公告)日：2022-11-17
申请号：US17625226
申请日：2020-07-11
IPC分类号： G01N33/574 , C12Q1/6886
摘要： The present invention includes methods of detecting follicular regulatory T cells (TFR) comprising: obtaining a biological sample from a subject and detecting whether TFR are increased in the tumor sample by contacting the biological sample with antibodies that detect CD3+CD4+ FOXP3+BCL6+ T cells CD3+CD4+CXCR5+GITR+ T cells, or both, when compared to a healthy subject, and detecting the increase of TFR in the tumor sample. The present invention also includes combination therapy that depletes follicular regulatory T cells (TFR) with minimal effect on regulatory T cells (TREGS) to prevent or reduce immune related adverse effects (irAEs).
-
公开(公告)号：US20210145768A1
公开(公告)日：2021-05-20
申请号：US17048059
申请日：2019-04-15
发明人： Klaus LEY , Marco ORECCHIONI
IPC分类号： A61K31/11 , A61P37/02 , C12N15/113
摘要： This disclosure provides agents that are useful for modulating an immune response in subject and for treating diseases, such as autoimmune diseases, cardiovascular diseases, infectious diseases, and cancer. These agents may comprise an olfactory receptor (OLFR), an OLFR ligand, or a protein involved in the trafficking of an OLFR to the plasma membrane of a cell. Alternatively, the agents may modulate the expression or activity of an OLFR, OLFR ligand, or protein involved in the trafficking of the OLFR to the plasma membrane of a cell.
-
公开(公告)号：US10723750B2
公开(公告)日：2020-07-28
申请号：US15775770
申请日：2016-11-14
IPC分类号： C07H15/04 , A61K47/65 , A61P37/04 , A61P31/12 , A61P35/00 , A61K31/7028 , A61K31/739 , C07H15/18 , C07H15/06
摘要： The compounds, compositions and methods provided herein antagonize, inhibit, decrease, reduce, suppress, or disrupt CD1d-mediated, iNKT cell-mediated, and/or iNKT cell TCR-mediated immune signaling. The sphingamide compounds were rationally designed based upon 3D structural considerations in relation to the structures of each of CD1d, the iNKT cell TCR, and the ternary complex CD1d-a-GalCer analog lipids-TCR. More specifically, the addition of an amide in the phytosphingosine tail of a derivative of α-GalCer led to a non-conserved binding with CD1d, a conserved binding with the iNKT cell TCR, and an antagonist-like phenotype.
-
公开(公告)号：US10556936B2
公开(公告)日：2020-02-11
申请号：US16303980
申请日：2017-05-29
摘要： The invention relates to novel immunogenic polypeptides identified in house dust mites and storage mites, which have the potential to be used in allergy immunotherapy, for diagnostic purposes, eventually via production of antibodies binding the polypeptide or for characterising allergen extracts of house dust mites and storage mites.
-
公开(公告)号：US20190256541A1
公开(公告)日：2019-08-22
申请号：US15775770
申请日：2016-11-14
IPC分类号： C07H15/04 , C07H15/18 , A61P31/12 , A61P35/00 , A61P37/04 , A61K47/65 , A61K31/7028 , A61K31/739
摘要： The compounds, compositions and methods provided herein antagonize, inhibit, decrease, reduce, suppress, or disrupt CD1d-mediated, iNKT cell-mediated, and/or iNKT cell TCR-mediated immune signaling. The sphingamide compounds were rationally designed based upon 3D structural considerations in relation to the structures of each of CD1d, the iNKT cell TCR, and the ternary complex CD1d-a-GalCer analog lipids-TCR. More specifically, the addition of an amide in the phytosphingosine tail of a derivative of α-GalCer led to a non-conserved binding with CD1d, a conserved binding with the iNKT cell TCR, and an antagonist-like phenotype.
-
公开(公告)号：US20180207228A1
公开(公告)日：2018-07-26
申请号：US15739440
申请日：2016-07-01
申请人： ALK-Abelló A/S
发明人： Claus Lundegaard , Shashank Gupta , Bjoern Peters , Susanne Sønderkær , Jens Brimnes , Peter Adler Würtzen , Helene Henmar , Thomas Christian Mygind , Lise Lund Mærkedahl
摘要： The invention relates to combinations of peptides derived from a portion of an amino sequence of a grass pollen allergen, e.g. the allergens Phl p 1, Phl p 2, Phl p 3, Phl p 4 and/or Phl p 5, or a peptide variant thereof. Such peptides comprise at least one T cell epitope mid a high number of patients in a worldwide population will have HLA Class II alleles with the potential to bind the peptides of the peptide combinations. The invention also relates to the use of such peptide combinations in relieving an immune response caused by grass pollen species.
-
公开(公告)号：US09694058B2
公开(公告)日：2017-07-04
申请号：US12446729
申请日：2007-10-25
IPC分类号： A61K39/00 , C12N5/071 , C07K14/52 , C07K14/705
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/6006 , C07K14/70575 , C12N5/067 , C12N5/0672 , C12N2501/105 , C12N2501/11 , C12N2501/33 , C12N2503/02
摘要： The tumor-necrosis factor superfamily member LIGHT (p30; TNFSF-14) is a cytokine for inducing immune responses against tumors. A novel biochemical approach is used to decorate the surface of tumor cells with LIGHT. LIGHT decorated cells can be used to vaccinate and induce effective, sustained immunity against cells expressing neo or pathogen associated antigens. Variants of LIGHT are described that enhance binding to cellular receptors (e.g., LT beta receptor) and decrease regulation by inhibitors (e.g., Decoy Receptor 3) increasing ability to stimulate immunity.
-
-
-
-
-
-
-
-
-
搜索结果
110 条记录 (耗时 0.075 秒)
